Their data suggested that elevation of AKAP1 in high-grade tumors enhances activation of the mammalian target of the rapamycin (mTOR) pathway by direct interaction with an mTORC1 inhibitor, sestrin2, providing new mechanistic insight into the role of AKAP1 in tumor growth [58]. Here, MTOR is linked to neoplasm.